Resmetirom for treatment of MASH
- PMID: 38848671
- DOI: 10.1016/j.cell.2024.05.009
Resmetirom for treatment of MASH
Abstract
Resmetirom is an oral selective THR-β agonist conditionally approved for the treatment of patients with noncirrhotic MASH with moderate to advanced fibrosis. Resmetirom restores mitochondrial and hepatic metabolic function; reduces atherogenic lipids; improves hepatic steatosis, inflammation, and fibrosis; and has no significant effect on THR-α. To view this Bench to Bedside, open or download the PDF.
Copyright © 2024 Elsevier Inc. All rights reserved.
Similar articles
-
Resmetirom: First Approval.Drugs. 2024 Jun;84(6):729-735. doi: 10.1007/s40265-024-02045-0. Epub 2024 May 21. Drugs. 2024. PMID: 38771485
-
The first MASH drug therapy on the horizon: Current perspectives of resmetirom.Liver Int. 2024 Jul;44(7):1526-1536. doi: 10.1111/liv.15930. Epub 2024 Apr 5. Liver Int. 2024. PMID: 38578141 Review.
-
Intrahepatic hypothyroidism in MASLD: Role of liver-specific thyromimetics including resmetirom.Diabetes Metab Syndr. 2024 May;18(5):103034. doi: 10.1016/j.dsx.2024.103034. Epub 2024 May 4. Diabetes Metab Syndr. 2024. PMID: 38714040 Review.
-
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.Lancet. 2019 Nov 30;394(10213):2012-2024. doi: 10.1016/S0140-6736(19)32517-6. Epub 2019 Nov 11. Lancet. 2019. PMID: 31727409 Clinical Trial.
-
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000. N Engl J Med. 2024. PMID: 38324483 Clinical Trial.
Cited by
-
Anti-tumor immunity relies on targeting tissue homeostasis through monocyte-driven responses rather than direct tumor cytotoxicity.bioRxiv [Preprint]. 2025 Mar 6:2024.06.12.598563. doi: 10.1101/2024.06.12.598563. bioRxiv. 2025. PMID: 38903113 Free PMC article. Preprint.
-
Mouse Models for the Study of Liver Fibrosis Regression In Vivo and Ex Vivo.J Clin Transl Hepatol. 2024 Nov 28;12(11):930-938. doi: 10.14218/JCTH.2024.00212. Epub 2024 Oct 11. J Clin Transl Hepatol. 2024. PMID: 39544245 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical